Exploring the association between use of gonadotropin releasing hormones agonists and prostate cancer diagnosis per se and diabetes control in men with type 2 diabetes mellitus: a nationwide, population-based cohort study

BACKGROUND: Gonadotropin Releasing Hormones agonists (GnRH), which are first line treatment for metastatic prostate cancer (PCa), increase risk of type 2 diabetes mellitus (T2DM). This study aims to quantify the association of use of GnRH with diabetes control in PCa men with T2DM. METHODS: Nationwi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, E., Garmo, Hans, Van Hemelrijck, Mieke, Adolfsson, Jan, Stattin, Pär, Zethelius, Björn, Crawley, Danielle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607667/
https://www.ncbi.nlm.nih.gov/pubmed/34809595
http://dx.doi.org/10.1186/s12885-021-08941-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607667/
https://www.ncbi.nlm.nih.gov/pubmed/34809595
http://dx.doi.org/10.1186/s12885-021-08941-y

Ejemplares similares